Prognostic value of Alzheimer's biomarkers in mild cognitive impairmentCitation formats

  • Authors:
  • Alzheimer’s Disease Neuroimaging Initiative

Standard

Prognostic value of Alzheimer's biomarkers in mild cognitive impairment : the effect of age at onset. / Alzheimer’s Disease Neuroimaging Initiative.

In: Journal of Neurology, 2019.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Alzheimer’s Disease Neuroimaging Initiative. / Prognostic value of Alzheimer's biomarkers in mild cognitive impairment : the effect of age at onset. In: Journal of Neurology. 2019.

Bibtex

@article{448b176cd8bd418d84462020c6a2eb0a,
title = "Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset",
abstract = "OBJECTIVE: The aim of this study is to assess the impact of age at onset on the prognostic value of Alzheimer's biomarkers in a large sample of patients with mild cognitive impairment (MCI).METHODS: We measured Aβ42, t-tau, hippocampal volume on magnetic resonance imaging (MRI) and cortical metabolism on fluorodeoxyglucose-positron emission tomography (FDG-PET) in 188 MCI patients followed for at least 1 year. We categorised patients into earlier and later onset (EO/LO). Receiver operating characteristic curves and corresponding areas under the curve (AUCs) were performed to assess and compar the biomarker prognostic performances in EO and LO groups. Linear Model was adopted for estimating the time-to-progression in relation with earlier/later onset MCI groups and biomarkers.RESULTS: In earlier onset patients, all the assessed biomarkers were able to predict cognitive decline (p < 0.05), with FDG-PET showing the best performance. In later onset patients, all biomarkers but t-tau predicted cognitive decline (p < 0.05). Moreover, FDG-PET alone in earlier onset patients showed a higher prognostic value than the one resulting from the combination of all the biomarkers in later onset patients (earlier onset AUC 0.935 vs later onset AUC 0.753, p < 0.001). Finally, FDG-PET showed a different prognostic value between earlier and later onset patients (p = 0.040) in time-to-progression allowing an estimate of the time free from disease.DISCUSSION: FDG-PET may represent the most universal tool for the establishment of a prognosis in MCI patients and may be used for obtaining an onset-related estimate of the time free from disease.",
author = "{Alzheimer{\textquoteright}s Disease Neuroimaging Initiative} and Daniele Altomare and Clarissa Ferrari and Anna Caroli and Samantha Galluzzi and Annapaola Prestia and {van der Flier}, {Wiesje M} and Rik Ossenkoppele and {Van Berckel}, Bart and Frederik Barkhof and Teunissen, {Charlotte E} and Anders Wall and Carter, {Stephen F} and Michael Sch{\"o}ll and Choo, {I L Han} and Timo Grimmer and Alberto Redolfi and Agneta Nordberg and Philip Scheltens and Alexander Drzezga and Frisoni, {Giovanni B}",
year = "2019",
doi = "10.1007/s00415-019-09441-7",
language = "English",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",

}

RIS

TY - JOUR

T1 - Prognostic value of Alzheimer's biomarkers in mild cognitive impairment

T2 - the effect of age at onset

AU - Alzheimer’s Disease Neuroimaging Initiative

AU - Altomare, Daniele

AU - Ferrari, Clarissa

AU - Caroli, Anna

AU - Galluzzi, Samantha

AU - Prestia, Annapaola

AU - van der Flier, Wiesje M

AU - Ossenkoppele, Rik

AU - Van Berckel, Bart

AU - Barkhof, Frederik

AU - Teunissen, Charlotte E

AU - Wall, Anders

AU - Carter, Stephen F

AU - Schöll, Michael

AU - Choo, I L Han

AU - Grimmer, Timo

AU - Redolfi, Alberto

AU - Nordberg, Agneta

AU - Scheltens, Philip

AU - Drzezga, Alexander

AU - Frisoni, Giovanni B

PY - 2019

Y1 - 2019

N2 - OBJECTIVE: The aim of this study is to assess the impact of age at onset on the prognostic value of Alzheimer's biomarkers in a large sample of patients with mild cognitive impairment (MCI).METHODS: We measured Aβ42, t-tau, hippocampal volume on magnetic resonance imaging (MRI) and cortical metabolism on fluorodeoxyglucose-positron emission tomography (FDG-PET) in 188 MCI patients followed for at least 1 year. We categorised patients into earlier and later onset (EO/LO). Receiver operating characteristic curves and corresponding areas under the curve (AUCs) were performed to assess and compar the biomarker prognostic performances in EO and LO groups. Linear Model was adopted for estimating the time-to-progression in relation with earlier/later onset MCI groups and biomarkers.RESULTS: In earlier onset patients, all the assessed biomarkers were able to predict cognitive decline (p < 0.05), with FDG-PET showing the best performance. In later onset patients, all biomarkers but t-tau predicted cognitive decline (p < 0.05). Moreover, FDG-PET alone in earlier onset patients showed a higher prognostic value than the one resulting from the combination of all the biomarkers in later onset patients (earlier onset AUC 0.935 vs later onset AUC 0.753, p < 0.001). Finally, FDG-PET showed a different prognostic value between earlier and later onset patients (p = 0.040) in time-to-progression allowing an estimate of the time free from disease.DISCUSSION: FDG-PET may represent the most universal tool for the establishment of a prognosis in MCI patients and may be used for obtaining an onset-related estimate of the time free from disease.

AB - OBJECTIVE: The aim of this study is to assess the impact of age at onset on the prognostic value of Alzheimer's biomarkers in a large sample of patients with mild cognitive impairment (MCI).METHODS: We measured Aβ42, t-tau, hippocampal volume on magnetic resonance imaging (MRI) and cortical metabolism on fluorodeoxyglucose-positron emission tomography (FDG-PET) in 188 MCI patients followed for at least 1 year. We categorised patients into earlier and later onset (EO/LO). Receiver operating characteristic curves and corresponding areas under the curve (AUCs) were performed to assess and compar the biomarker prognostic performances in EO and LO groups. Linear Model was adopted for estimating the time-to-progression in relation with earlier/later onset MCI groups and biomarkers.RESULTS: In earlier onset patients, all the assessed biomarkers were able to predict cognitive decline (p < 0.05), with FDG-PET showing the best performance. In later onset patients, all biomarkers but t-tau predicted cognitive decline (p < 0.05). Moreover, FDG-PET alone in earlier onset patients showed a higher prognostic value than the one resulting from the combination of all the biomarkers in later onset patients (earlier onset AUC 0.935 vs later onset AUC 0.753, p < 0.001). Finally, FDG-PET showed a different prognostic value between earlier and later onset patients (p = 0.040) in time-to-progression allowing an estimate of the time free from disease.DISCUSSION: FDG-PET may represent the most universal tool for the establishment of a prognosis in MCI patients and may be used for obtaining an onset-related estimate of the time free from disease.

U2 - 10.1007/s00415-019-09441-7

DO - 10.1007/s00415-019-09441-7

M3 - Article

C2 - 31267207

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -